Pfizer’s RSV vaccine for pregnant women protects newborns against severe illness
Pfizer announced on Tuesday that an experimental RSV vaccine for pregnant women protects newborns against severe illness for at least six months after birth. In phase III of a randomized, double-blind, placebo-controlled study, considered the gold standard of epidemiologic studies, the vaccine was found to be about 82% effective at preventing severe cases of respiratory…